SGLT2 Inhibitors and Cardiovascular Outcomes in Patients With Moderate-to-Severe Psoriasis Receiving Biologic Therapy: A Propensity Score-Matched Cohort Study
SGLT2 Inhibitors and Cardiovascular Outcomes in Patients With Moderate-to-Severe Psoriasis Receiving Biologic Therapy: A Propensity Score-Matched Cohort Study. // Actas Dermo-Sifiliográficas. – URL: https://www.sciencedirect.com/science/article/pii/S0001731026001663?dgcid=rss_sd_all
SGLT2 Inhibitors and Cardiovascular Outcomes in Patients With Moderate-to-Severe Psoriasis Receiving Biologic Therapy: A Propensity Score-Matched Cohort Study. Actas Dermo-Sifiliográficas. https://www.sciencedirect.com/science/article/pii/S0001731026001663?dgcid=rss_sd_all
“SGLT2 Inhibitors and Cardiovascular Outcomes in Patients With Moderate-to-Severe Psoriasis Receiving Biologic Therapy: A Propensity Score-Matched Cohort Study.” Actas Dermo-Sifiliográficas.
@article{article32877,
title = {SGLT2 Inhibitors and Cardiovascular Outcomes in Patients With Moderate-to-Severe Psoriasis Receiving Biologic Therapy: A Propensity Score-Matched Cohort Study},
journal = {Actas Dermo-Sifiliográficas},
url = {https://www.sciencedirect.com/science/article/pii/S0001731026001663?dgcid=rss_sd_all}
}
ABSTRACT Angioimmunoblastic T‐cell lymphoma (AITL) is a peripheral T‐cell lymphoma derived from T‐follicular helper cells that frequently exhibits cutaneous involvement with highly variable clinical manifestations. We report a...
Purpose Adoption of whole slide imaging (WSI) is accelerating across anatomic pathology practices, yet there is a lack of evidence guiding its use for infectious disease diagnoses. WSI systems usually operate at a maximum of 40X...